Monthly Archives: September 2014

American Calcar v. Amer. Honda Motor Co. – Therasense Goes Out For a Test Drive

On Friday, in American Calcar v. Amer. Honda Motor Co., App. No. 2013-1061 (Fed. Cir., September 26, 2014) a divided Fed. Cir. panel affirmed the district court’s ruling, following remand, that three patents on a multimedia system for vehicle information … Continue reading

Posted in Inequitable Conduct/Rule 56 | Tagged , , , , , , , | 1 Comment

PLANET BLUE v. NAMCO – Abstract at the “Point of Novelty”

In McRO, Inc. d.b.a. Planet Blue v. Namco Bandai Games America, civ. No. CV 12-10322-GW (FFMx) (C. D. Cal., Sept. 22, 2014), the granted Defendant’s motion for judgment on the pleadings that US Patent numbers 6,307,576 and 6,611, 278, were … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , | 1 Comment

Genetic Technologies v. LabCorp. – Mayo Redux.

It was Mayo redux with a vengeance in the September 23, 2014 decision in Genetic Technologies Ltd. v. Laboratory Corp. of Amer. Holdings et al., Civil Action No. 12-1736-LPS-CJB (D. Del. 2014).  Magistrate Judge Burke released an opinion invalidating claim … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , | 2 Comments

FDA Publishes “Purple Book” for Biologicals/Biosimilars

In a major move to get organized for the oncoming wave of biosimilar applications, the FDA has published a “Purple Book” listing licensed (e.g., approved) biologicals and licensed interchangeable biosimilars. Rather than summarize the contents table of the book, linked … Continue reading

Posted in 2017 Patent Review | Tagged , , , , | Leave a comment